Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
From the PDF:
"During the majority of the financial year, Scancell’s share price fluctuated within a band of between 20p and 24p. From mid-January 2022, the Scancell share price entered a period of steady decline before recovering to 16.75p at 19 April following the announcement of the start of Modi-1 trials.
While it could be argued that Scancell has had a quiet year in terms of news flow and corporate milestones, the substantial injections of equity funding during 2020 have allowed Scancell to invest heavily in its technology platforms. Founder Professor Lindy Durrant is now back at the helm as CEO and Chief Scientific Officer, and Dr Richard Goodfellow is back as Interim Chief Business Officer. There have been subtle changes in the way Scancell positions itself in the market, the company now describing itself as a “clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease.
The company is building a pipeline of innovative products by utilising its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies”.
I remain positive about Scancell’s potential for treating otherwise untreatable diseases. Arguably the most important announcement made by Scancell during the course of the last 12 months was the news that the redemption date of the c. £19.7m of convertible loan notes held by Scancell’s major funder, US-based Redmile Group, LLC, were extended by three years (from 2022 to 2025), reducing the risk of an unfavourable dilutive event in 2022 and giving Scancell’s management the time to create maximum commercial value from its multiple ‘shots on goal’.
Post period end Scancell has received approval from the South Africa authorities to extend the scope of its Covidity trial.
As at the period end, Scancell made up 21% of OT3’s NAV, making it the Company’s second largest portfolio holding.
I think the other thing that may have prompted the most recent, and short-lived, surge in SAR was GSK's acquisition of Sierra to whom SAR have out-licensed one of their compounds. Lots of excitable conclusions being made over there, but it does not automatically follow that GSK will now buy out SAR.
Permission to shout BRAVO!
https://youtu.be/4vpfl9w6mbs
I have emailed admin twice and also contacted FTI (the IR firm behind the RNS) but still no action. LSE say that they have no direct control on what RNSs appear on their site (WHAT??) but that they have been in touch with their 'data supplier' and need to wait for them to send the information over to LSE in order for the RNS (and accompanying red dot) to appear.
Shocking
Scancell progresses its new anti-glycan monoclonal antibody (mAb) platform GlyMab™
Initial anti-glycan mAbs from the GlyMab™ platform have now been successfully humanised
Fourth research agreement on Glymab™ platform signed with major European Pharma.
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides an update on its anti-glycan monoclonal antibody (mAb) platform, now branded GlyMab™. The Company’s fourth proprietary platform has the potential to expand further its pipeline of novel anti-cancer mAbs and the versatility to yield other drug formats including antibody drug conjugate and CAR-T candidates. Scancell is developing a unique pipeline of tumour-specific anti-glycan antibodies with the initial aim of generating early-stage clinical data, either alone or in combination with potential strategic partners.
The Company currently has a pipeline of five anti-glycan mAbs: SC129, SC134, SC88 and SC27 that target solid tumours including pancreatic, small cell lung, colorectal and gastric, and SC2811 that targets a glycolipid on T cell stem cells. Four (SC129, SC27, SC134 and SC88) out of five of these drug candidates have now been successfully humanised and are therefore ready for the next stage of development.
In addition, the company is pleased to announce its fourth research collaboration agreement based on the Glymab™ platform. The agreement is with a major European pharmaceutical company and is designed to further evaluate one of the company’s Glymab™ antibodies for the treatment of cancer.
https://100days.cepi.net/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/
The CEPI tweet about developing a universal Covid vaccine (and SCLP as a contender) was originally tweeted in March 2021. However, it has just been retweeted, by CEPI, this afternoon. Could the timing be significant, I wonder...?
https://twitter.com/CEPIvaccines/status/1492840897050025986?t=FIHXH3oVM93xVZr2ZONrzw&s=09
Hi Cleaner. It looks to me like aggregated content designed as clickbait to sell their report. In other words, they slot SCLP numbers into a templated 'framework' article about debt, but next week, it could just as easily be VAL, SAR etc...I think the giveaway is that they do not mention SVIB, SCOV, Covid, Covidity, Moditope, avidimab, glycans etc anywhere on the piece, nor is there any mention of SCLP personnel, Redmile, Vulpes whatsoever. It's lazy journalism in many ways, but linking SCLP in a headline about debt draws people in, nonetheless and they may get a few sign-ups and even sell a 'report' or two...AIMHO.
In a speech at the Francis Crick Institute in London, the Health Secretary will announce an eight-week “call for evidence” to inform a 10-year plan, to be published later in the year.
“Let this be the day where we declare a national war on cancer,” he is expected to tell scientists, promising a plan which “learns the lessons from the pandemic” and applies the advances to cancer care.
The Health Secretary is expected to promise “a far-reaching look at how we want cancer care to be in 2032” encompassing prevention, diagnosis, treatment and vaccines.
Officials are working on plans to intensify research on mRNA vaccines for cancer, bringing together learning gained through the pandemic, with expertise in cancer immunotherapy treatment